90
Views
6
CrossRef citations to date
0
Altmetric
Review

Limiting and controlling carbapenem-resistant Klebsiella pneumoniae

&
Pages 9-14 | Published online: 10 Dec 2013

Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) is resistant to almost all antimicrobial agents, is associated with substantial morbidity and mortality, and poses a serious threat to public health. The ongoing worldwide spread of this pathogen emphasizes the need for immediate intervention. This article reviews the global spread and risk factors for CRKP colonization/infection, and provides an overview of the strategy to combat CRKP dissemination.

Introduction

During the last decade, carbapenem-resistant Klebsiella pneumoniae (CRKP) has spread throughout the world, becoming a matter of great concern. CRKP was first reported in the United States in 2001 in North Carolina.Citation1 The first case outside the United States occurred in France, where a patient who had been hospitalized in New York carried the strain with him.Citation2 Since then, CRKP has been reported in Europe,Citation3Citation8 the Middle East,Citation9Citation12 South America,Citation13,Citation14 and the Far East.Citation15,Citation16 Several outbreaks of CRKP have occurred around the world as described in .Citation3,Citation4,Citation9Citation11,Citation13,Citation14,Citation16Citation18 These outbreaks have been associated with the plasmid-encoded carbapenemase K. pneumoniae carbapenemase (KPC), a carbapenem-hydrolyzing β-lactamase.Citation19 CRKP isolates are resistant to almost all available antimicrobials. These isolates are susceptible only to polymyxins and tigecycline; a minority are also susceptible to the few remaining aminoglycosides, though resistance to these agents is worrisomely increasingly reported.Citation20,Citation21

Table 1 Outbreaks of CRKP described around the globe

K. pneumoniae, an inhabitant of the gastrointestinal tract, skin, and nasopharynx, can cause infection in many parts of the body, including urinary tract infections, hospital acquired pneumonia, intra-abdominal infections, wound infections, and primary bacteremia.Citation22Citation24 Initially, CRKP seemed to be limited to causing hospital acquired infections, though further on, CRKP has spread in different health care systems, including long-term care facilities.Citation25Citation29 The mortality rate of CRKP infections (mainly bacteremia) seems strikingly high, 30%–50%.Citation17,Citation30Citation32

Predictors for CRKP colonization

Several investigators have evaluated predictors for CRKP colonization. The following summarizes various studies.

  • Poor functional status, intensive care unit (ICU) stay, and the recipient of antibiotics were predictors of CRKP colonization in a study by Schwaber et al.Citation31 Exposure to fluoroquinolones was independently predictive of CRKP isolation.

  • Nursing home residency before hospital admission, bedridden status, and previous antibiotic therapy were demonstrated to predict CRKP colonization in a study by Borer et al.Citation33

  • Previous use of carbapenem and cephalosporin were found to predict CRKP colonization in a study by Kwak et al.Citation34 Nosocomial isolation of CRKP was strongly favored by the selection pressure of carbapenem. In this study, prior treatment with fluoroquinolones was associated with decreased risk for the emergence of CRKP.

Risk factors for CRKP infection

Risk factors for acquisition of CRKP infection by patients initially colonized with CRKP have been researched, results are listed below.

  • Diabetes mellitus, solid tumors, previous invasive procedures, tracheostomy, urinary catheter insertion, and antipseudomonal penicillin therapy were risk factors for the acquisition of CRKP infection in a study by Borer et al.Citation33 Carbapenem use was strongly predictive of CRKP infection.

  • ICU admission (within 2 weeks) or prior exposure to carbapenems or glycopeptides were independent risk factors for the acquisition of nosocomial CRKP infections in a study by Wu et al.Citation35

  • Antibiotic use, especially colistin, presence of a urinary catheter, surgery, invasive procedures, and ICU admission were risk factors for the acquisition of CRKP infection in a study by Shilo et al.Citation22

  • In a multivariate analysis, prior use of macrolides and any antibiotic exposure ≥14 days remained the only independent factors associated with CRKP bacteremia in a study by Hussein et al.Citation36 In a univariate analysis, CRKP bacteremia was associated with hematological malignancy, chronic renal failure, chronic liver disease, previous bone marrow transplantation, longer length of stay before the onset of bacteremia, receipt of mechanical ventilation, central venous catheterization, dialysis, and stay in the ICU or hematology department.Citation36

  • Independent predictors of subsequent carbapenem-resistant Enterobacteriaceae (CRE) infection were admission to the ICU, having a central venous catheter, receipt of antibiotics, and diabetes mellitus in a study by Schechner et al.Citation37

Persistent CRKP colonization

Persistent gastrointestinal carriage of CRKP is associated with (any) catheter use and a low functional status. It is more common in patients with recent CRKP acquisition (≤4 months) and related to residence in a long-term care facility.Citation38 Multiple hospitalizations and CRKP disease extend the duration of carriage, with colonization detected after 12 months in 39% of carriers.Citation39

Dissemination of CRKP represents a serious threat to public health.Citation40,Citation41 The fact that CRKP strains have spread worldwide, the lack of proven clinically efficacious antibiotics, and the presence of gene-encoded KPC enzymes residing on transmissible plasmids makes the control of CRKP infections an imperative task of health care systems.Citation42

The Centers for Disease Control and Prevention, as well as a meeting of national experts in Europe, have published new infection control recommendations and strategies to combat this public health concern.Citation40,Citation43 We aim to present a multifaceted intervention strategy to limit and control CRKP spread in health care systems based on these guidelines, the Israeli nationwide intervention, our personal experience, and the current literature.

Strategy for preventing CRKP dissemination in hospitals

We suggest applying a comprehensive infection control intervention in acute care hospitals, comprising of bundles of infection control measures:

  1. Flagging system

    1. Active surveillance culture on hospital admission

    2. Pre-emptive contact isolation pending cultures

  2. Building of cohort space or ward for CRKP positive patients

  3. Intensive active surveillance in high-risk wards

  4. Epidemiological investigations

  5. Staff education

  6. New antibiotic restriction policy

  7. Addressing risk factors

  8. Other interventions.

In addition, a dedicated full-time infection control practitioner is needed to handle the collection and daily analysis of data.

Flagging system

On entering the emergency room, a clerk identifies high-risk patients (prior to hospital admission) and places an identification mark (ie, a red sticker) on the patient’s chart. High-risk patients for CRKP colonization include patients transferred from other hospitals, patients who were hospitalized in other hospitals in the past 6 months, and patients residing in long-term care facilities. Risk factors are then verified by nurses who sign the verification stamp. Patients known to be colonized with CRKP within the past 12 months, who do not have a negative rectal polymerase chain reaction (PCR), are admitted to the cohort.

Active surveillance culture on ward admission

Rectal cultures using rectal swabs are performed for all high-risk patients on ward admission by the ward’s nurse. Cultures are sent directly to the bacteriology laboratory for prompt CRKP identification.

Pre-emptive contact isolation pending cultures

All high-risk patients are placed in pre-emptive isolation in the wards pending admission surveillance culture results. Strict contact precautions are applied (ie, use of gown and gloves by health care workers); signage is applied on the entrance to the high-risk patient’s room; 1:4 ratio of trained nurses to patients; a dedicated housekeeping team. Patients with a positive rectal culture for CRKP are transferred to a cohort area for maximal contact isolation. Patients with a negative rectal culture for CRKP remain in the ward and are treated using standard precautions.

Building of cohort space or ward for CRKP positive patients

Cohort space should be designed as a separate ward or as part of an existing ward, sectioned off with clear signage. The number of beds should address the expected number of patients. An exclusively dedicated nursing staff should be assigned. The cohort is supplied with its own equipment, including an X-ray machine, electrocardiogram machine, and monitors. Disposable stethoscope, blood pressure cuff, and thermometers should also be supplied. The physician in charge is not fully dedicated to the cohort, but complies with strict contact precautions. Strict patient isolation is applied by the dedicated nursing personnel. A dedicated housekeeping team is trained for cleaning and disinfecting CRKP positive patients’ units during hospitalization and after discharge.

Environmental disinfection using 2,000 ppm chlorine for 10 minutes is done twice daily; 70% alcohol is used for computers and monitors. Patients undergo daily whole-body disinfection with antiseptics (chlorhexidine); this method has been proven efficacious in preventing bloodstream infections.Citation44,Citation45

Visitors require patient permission and are educated about hand hygiene, use of gowns, gloves, etc. It is best to limit visitors’ number to a minimum. Immune suppressed people and children are not allowed to enter the cohort space.

All hospitalized patients colonized/infected with CRKP are transferred to this ward if their medical condition allows (providing the cohort ward can continue the treatment they received up to this point).

Intensive active surveillance in high-risk wards

High-risk wards identified by CRKP incidence are targeted for interventions, such as ICUs and step-down units.Citation46Citation48 In our hospital, neurology and geriatric wards were also included.Citation42 All patients in these wards undergo rectal cultures for CRKP detection on admission and once weekly until they are discharged (to detect in-hospital transmission). Patients with a rectal culture positive for CRKP should be transferred to a cohort area for maximal contact isolation.

Epidemiologic investigations

Identification of new CRKP colonized/infected patients within the hospital prompt an immediate and intensive review of case and contacts by the infectious control practitioner, enforcement of compliance with hand hygiene, contact precautions, and disinfectant protocols. Rectal cultures from patients who shared a room with the case are performed due to the possibility of cross-infection between roommates. The timely identification of colonized and/or infected patients is critical to the success of interrupting cross-transmission of CRE in health care facilities.Citation23

In the case of an outbreak or clusters, cultures of health care workers’ hands and environmental cultures are performed at the discretion of the hospital epidemiologist.

Staff education

Physicians, staff nurses, nursing aids, and housekeeping teams all receive training on the relevance of CRKP and its route of transmission.Citation49 Familiarizing health care personnel with proper hand hygiene technique as well as its rationale is very important.Citation40 Pamphlets explaining hand hygiene are placed in relevant areas for staff and family. Hand hygiene adherence is monitored and feedback is provided, ensuring maximal compliance. Hand hygiene stations are readily accessible (clean sinks and/or alcohol-based hand rubs).Citation40 Revision and strict adherence to contact precautions is of paramount importance; this should also be monitored.

Antibiotic restrictive policy

We advise restriction of carbapenem use by infectious diseases specialists, using rigorous policy enforcement where approval of empiric carbapenem use requires the agreement of two infectious diseases physicians. We have also limited the number of carbapenems for use; meropenem is the only agent of this class available in our hospital.

Addressing risk factors

Early identification of risk factors for subsequent infection among CRKP-colonized patients can help in controlling modifiable risk factors (ie, central catheters, urinary catheters, invasive procedures, antibiotic use) and targeting appropriate empirical therapy to minimize morbidity and mortality.

Other interventions

Selective digestive decontamination of the gastrointestinal tract with oral gentamicinCitation50 or a combination of oral gentamicin and colistinCitation51 may be used cautiously in a selective patient population, such as transplant recipients or immunocompromised patients colonized with CRKP pending chemotherapy, as well as patients colonized with CRKP who require major intestinal or oropharyngeal surgery.

These interventions have greatly reduced the incidence of colonization and clinical infection with CRKP:

  • Ben-David et al used active surveillance during a hospital-wide outbreak of CRKP and showed a 4.7-fold decrease in the incidence of clinical infection, from 6.93 to 1.8 cases per 10,000 patient days.Citation46

  • Borer et al used a multifaceted strategy during a hospital-wide outbreak of CRKP and reduced the infection density from 5.26 to 0.18 cases per 10,000 patient days.Citation42

  • Ciobotaro et al used a multidisciplinary intervention to limit the spread of an epidemic CRKP strain and had a 16-fold decrease in CRKP incidence, from 6.6 to 0.5 clinical cases per 10,000 patient days, sustained for 30 months.Citation52 Cross-infection decreased from 6.0% to 2.7%.

  • Schwaber et al and the Israeli CRE Working Group enforced the Israel Ministry of Health guidelines mandating physical separation of hospitalized carriers of CRE and dedicated staffing and appointed a professional task force charged with containment.Citation19 The monthly incidence of nosocomial CRE was reduced from 55.5 to 11.7 cases per 100,000 patient days within 15 months.

  • Munoz-Price et al used a bundled intervention to control an outbreak of CRKP, successfully preventing horizontal spread of CRKP in a long-term acute care hospital despite ongoing admission of patients colonized with CRKP.Citation49

  • Kochar et al assessed the effect of enhanced infection control measures with screening for gastrointestinal colonization on limiting the spread of CRKP in a New York hospital endemic for this pathogen. These combined measures were helpful in reducing the incidence of CRKP in an ICU endemic for CRKP from 9.7±2.2 to 3.7±1.6 new patients per 1,000 patient days per quarter.Citation53

CRKP is not limited to acute-care facilities; control of CRKP in long-term care facilities seems to be an essential part to limiting and controlling the spread of this pathogen. Many components of the bundles used in hospitals to combat CRKP could probably be applied successfully in long-term care facilities. Working together on a local and regional level using a multifaceted approach should provide us with better tools to limit the spread of CRKP.

Disclosure

The authors report no conflicts of interest in this work.

References

  • YigitHQueenanAMAndersonGJNovel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniaeAntimicrob Agents Chemother20014541151116111257029
  • NaasTNordmannPVedelGPoyartCPlasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from FranceAntimicrob Agents Chemother200549104423442416189140
  • RobustilloRodela ADíaz-AgeroPérez CSanchezSagrado TRuiz-GarbajosaPPitaLópez MJMongeVEmergence and outbreak of carbapenemase-producing KPC-3 Klebsiella pneumoniae in Spain, Sep 2009 to Feb 2010: control measuresEuro Surveill2012177pii:20086
  • SteinmannJKaaseMGatermannSOutbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, Jul 2010 to Jan 2011Euro Surveill20111633pii:19944
  • BaboueeBWidmerAFDubuisOEmergence of four cases of KPC-2 and KPC-3-carrying Klebsiella pneumoniae introduced to Switzerland, 2009–2010Euro Surveill20111611pii:19817
  • OsterbladMKirveskariJKoskelaSFirst isolations of KPC-2-carrying ST258 Klebsiella pneumoniae strains in Finland, Jun and Aug 2009Euro Surveill20091440pii:19349
  • WoodfordNZhangJWarnerMArrival of Klebsiella pneumoniae producing KPC carbapenemase in the United KingdomJ Antimicrob Chemother20086261261126418812425
  • GianiTPiniBArenaFAMCLI-CRE Survey ParticipantsEpidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, May 15, to June 30, 2011Euro Surveill20131822pii:20489
  • SamraZOfirOLishtzinskyYMadar-ShapiroLBisharaJOutbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in IsraelInt J Antimicrob Agents200730652552917931835
  • Wiener-WellYRudenskyBYinnonAMCarriage rate of carbapenem-resistant Klebsiella pneumoniae in hospitalised patients during a national outbreakJ Hosp Infect201074434434919783067
  • BalkhyHHEl-SaedAAl JohaniSMThe epidemiology of the first described carbapenem-resistant Klebsiella pneumoniae outbreak in a tertiary care hospital in Saudi Arabia: how far do we go?Eur J Clin Microbiol Infect Dis20123181901190922237459
  • Navon-VeneziaSLeavittASchwaberMJIsraeli KPC Kpn Study GroupFirst report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United StatesAntimicrob Agents Chemother200953281882019029323
  • GregoryCJLlataEStineNOutbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variantInfect Control Hosp Epidemiol201031547648420334553
  • LopezJACorreaANavon-VeneziaSIntercontinental spread from Israel to Colombia of a KPC-3-producing Klebsiella pneumoniae strainClin Microbiol Infect2011171525620219078
  • RohKHLeeCKSohnJWSongWYongDLeeKIsolation of a Klebsiella pneumoniae isolate of sequence type 258 producing KPC-2 carbapenemase in KoreaKorean J Lab Med201131429830122016687
  • ZhangRWangXDCaiJCOutbreak of Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae with high qnr prevalence in a Chinese hospitalJ Med Microbiol201160Pt 797798221393450
  • SouliMGalaniIAntoniadouAAn outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomesClin Infect Dis201050336437320041768
  • CarbonneAThioletJMFournierSControl of a multi-hospital outbreak of KPC-producing Klebsiella pneumoniae type 2 in France, Sep to Oct 2009Euro Surveill20101548pii:19734
  • SchwaberMJLevBIsraeliAIsrael Carbapenem-Resistant Enterobacteriaceae Working GroupContainment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented interventionClin Infect Dis201152784885521317398
  • ChenLFAndersonDJPatersonDLOverview of the epidemiology and the threat of Klebsiella pneumoniae carbapenemases (KPC) resistanceInfect Drug Resist2012513314123055754
  • MarchaimDChopraTPogueJMOutbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, MichiganAntimicrob Agents Chemother201155259359921115786
  • ShiloSAssousMVLachishTRisk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: a case-control studyInfection201341250350923271210
  • TzouvelekisLSMarkogiannakisAPsichogiouMTassiosPTDaikosGLCarbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsClin Microbiol Rev201225468270723034326
  • LandmanDBabuEShahNTransmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustrationJ Antimicrob Chemother20126761427143122378678
  • PrabakerKLinMYMcNallyMCenters for Disease Control and Prevention (CDC) Prevention Epicenters ProgramTransfer from high-acuity long-term care facilities is associated with carriage of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae: a multihos-pital studyInfect Control Hosp Epidemiol201233121193119923143355
  • ViauRAHujerAMMarshallSH“Silent” dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in Northeast OhioClin Infect Dis20125491314132122492318
  • UrbanCBradfordPATuckmanMCarbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilitiesClin Infect Dis20084611e127e13018419424
  • Ben-DavidDMasarwaSNavon-VeneziaSIsrael PACF CRKP (Post-Acute-Care Facility Carbapenem-Resistant Klebsiella pneumoniae) Working GroupCarbapenem-resistant Klebsiella pneumoniae in post-acute-care facilities in IsraelInfect Control Hosp Epidemiol201132984585321828964
  • EndimianiADepasqualeJMForeroSEmergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare systemJ Antimicrob Chemother20096451102111019740911
  • BorerASaidel-OdesLRiesenbergKAttributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremiaInfect Control Hosp Epidemiol2009301097297619712030
  • SchwaberMJKlarfeld-LidjiSNavon-VeneziaSSchwartzDLeavittACarmeliYPredictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortalityAntimicrob Agents Chemother20085231028103318086836
  • MouloudiEProtonotariouEZagorianouABloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomesInfect Control Hosp Epidemiol201031121250125620973725
  • BorerASaidel-OdesLEskiraSRisk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniaeAm J Infect Control201240542142521906844
  • KwakYGChoiSHChooEJRisk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patientsMicrob Drug Resist200511216516915910232
  • WuDCaiJLiuJRisk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniaeSouth Med J2011104210611021258230
  • HusseinKRaz-PasteurAFinkelsteinRImpact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumoniaeJ Hosp Infect201383430731323313086
  • SchechnerVKotlovskyTKazmaMAsymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected?Clin Microbiol Infect201319545145622563800
  • FeldmanNAdlerAMolshatzkiNGastrointestinal colonization by KPC-producing Klebsiella pneumoniae following hospital discharge: duration of carriage and risk factors for persistent carriageClin Microbiol Infect2013194E190E19623331385
  • ZimmermanFSAssousMVBdolah-AbramTLachishTYinnonAMWiener-WellYDuration of carriage of carbapenem-resistant Enterobacteriaceae following hospital dischargeAm J Infect Control201341319019423449280
  • 2012 CRE Toolkit – Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE)AtlantaCenters for Disease Control and Prevention2013 Available from: http://www.cdc.gov/hai/organisms/cre/cre-toolkit/Accessed August 15, 2013
  • van der BijAKPitoutJDThe role of international travel in the worldwide spread of multiresistant EnterobacteriaceaeJ Antimicrob Chemother20126792090210022678728
  • BorerAEskiraSNativRA multifaceted intervention strategy for eradication of a hospital-wide outbreak caused by carbapenem-resistant Klebsiella pneumoniae in Southern IsraelInfect Control Hosp Epidemiol201132121158116522080653
  • GrundmannHLivermoreDMGiskeCGCNSE Working GroupCarbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national expertsEuro Surveill20101546pii:19711
  • Munoz-PriceLSHotaBStemerAWeinsteinRAPrevention of bloodstream infections by use of daily chlorhexidine baths for patients at a long-term acute care hospitalInfect Control Hosp Epidemiol200930111031103519751155
  • BorerAGiladJPoratNImpact of 4% chlorhexidine whole-body washing on multidrug-resistant Acinetobacter baumannii skin colonisation among patients in a medical intensive care unitJ Hosp Infect200767214915517900759
  • Ben-DavidDMaorYKellerNPotential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infectionInfect Control Hosp Epidemiol201031662062620370465
  • BilavskyESchwaberMJCarmeliYHow to stem the tide of carbapenemase-producing enterobacteriaceae?: proactive versus reactive strategiesCurr Opin Infect Dis201023432733120581673
  • CalfeeDJenkinsSGUse of active surveillance cultures to detect asymptomatic colonization with carbapenem-resistant Klebsiella pneumoniae in intensive care unit patientsInfect Control Hosp Epidemiol2008291096696818754738
  • Munoz-PriceLSHaydenMKLolansKSuccessful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospitalInfect Control Hosp Epidemiol201031434134720175685
  • ZuckermanTBenyaminiNSprecherHSCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier stateBone Marrow Transplant20114691226123021057549
  • Saidel-OdesLPolachekHPeledNA randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriageInfect Control Hosp Epidemiol2012331141922173517
  • CiobotaroPOvedMNadirEBardensteinRZimhonyOAn effective intervention to limit the spread of an epidemic carbapenem-resistant Klebsiella pneumoniae strain in an acute care setting: from theory to practiceAm J Infect Control201139867167721864942
  • KocharSSheardTSharmaRSuccess of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniaeInfect Control Hosp Epidemiol200930544745219301985